Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $9.92, but opened at $9.33. Telix Pharmaceuticals shares last traded at $9.29, with a volume of 59,117 shares trading hands.

Analysts Set New Price Targets

TLX has been the subject of several recent research reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. UBS Group reduced their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, September 23rd. Citigroup initiated coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a “buy” rating and a $22.00 price objective for the company. Finally, HC Wainwright dropped their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Price Performance

The business’s 50-day simple moving average is $10.03 and its 200 day simple moving average is $12.28.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TLX. Rhumbline Advisers increased its position in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the last quarter. IHT Wealth Management LLC purchased a new position in shares of Telix Pharmaceuticals during the second quarter worth approximately $213,000. Blair William & Co. IL purchased a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $217,000. JPMorgan Chase & Co. bought a new position in Telix Pharmaceuticals in the third quarter worth about $243,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.